首页 | 本学科首页   官方微博 | 高级检索  
     

健脾软肝煎治疗乙肝肝纤维化(肝郁脾虚证)30例疗效观察
引用本文:薛霁,郑万平,徐丹. 健脾软肝煎治疗乙肝肝纤维化(肝郁脾虚证)30例疗效观察[J]. 新中医, 2005, 37(12): 44-46
作者姓名:薛霁  郑万平  徐丹
作者单位:吉林大学,第二医院,中医科,吉林,长春,130041
摘    要:目的:观察健脾软肝煎治疗乙型肝炎肝纤维化(肝郁脾虚证)的临床疗效。方法:将60例患者随机分为2组各30例。治疗组口服健脾软肝煎(处方:党参、炒白术、茯苓、黄芪、当归、赤芍、丹参、炙鳖甲、莪术、水蛭、香附、白花蛇舌草、虎杖)治疗;对照组口服复方鳖甲软肝片治疗。疗程均为3月。观察临床疗效、症状体征改善情况及治疗前后肝功能、肝纤维化指标的变化。结果:显效率、总有效率治疗组分别为46.67%、86.67%,对照组分别为26.67%、70.00%,2组比较,差异均有显著性意义(P〈0.05)。2组治疗后肝功能指标均有改善,与治疗前比较,差异有显著性或非常显著性意义(P〈0.05,P〈0.01);2组肝功能治疗后比较,差异有显著性或非常显著性意义(P〈0.05,P〈0.01);治疗组改善肝纤维化HA、CIV指标与对照组治疗后比较,差异均有显著性意义(P〈0.05)。结论:健脾软肝煎对乙型肝炎肝纤维化(肝郁脾虚证)有较好的治疗效果。

关 键 词:肝纤维化 肝炎  乙型 肝郁脾虚 健脾软肝煎
文章编号:0256-7415(2005)12-0044-03
收稿时间:2005-07-24
修稿时间:2005-07-24

Treatment of Hepatitis B (Liver Stagnation and Spleen Deficiency Syndrome) with Hepatic Fibrosis by Jianpi Ruangan Jian: A Clinical Observation of 30 Cases
XUE Ji,ZHENG Wan-ping,XU Dan. Treatment of Hepatitis B (Liver Stagnation and Spleen Deficiency Syndrome) with Hepatic Fibrosis by Jianpi Ruangan Jian: A Clinical Observation of 30 Cases[J]. JOURNAL OF NEW CHINESE MEDICINE, 2005, 37(12): 44-46
Authors:XUE Ji  ZHENG Wan-ping  XU Dan
Affiliation:The Second Hospital of Jilin Universidty, Changchun 130041, China
Abstract:Objective: To observe the curative effect of Jianpi Ruangan Jian (JRJ) for hepatitis B hepatic fibrosis. Methods: 60 cases were allocated to 2 groups (each group 30 cases) randomly. The treatment group was treated by JRJ (composed of Radix Codonopsis, Rhizoma Atractylocis Macrocephalae, Poria, Radix Astragali, Radix Angelicae Sinensis, Radix Paeoniae Rubra, Radix Salviae Miltiorrhizae, Carapax Trionycis Preparata, Rhizoma Curcumae, Hirudo, Rhizoma Cyperi, Herba Hedyotis Diffusae and Rhizoma Polygoni Cuspidati); the control group by compound Biejia Ruangan Tablets. 3 months constituted the course of treatment. The curative effect, improvement of symptoms and signs, liver function and hepatic fibrosis before and after treatment were observed. Results: The markedly effective rate and total effective rate was 46. 67% and 86. 67% in treatment group and 26. 67% and 70. 00% in control group respectively ( P < 0. 05). The HA and CIV in hepatic fibrosis in treatment group were significantly different as comparied with control group after treatment (P < 0.05). Conclusion: JRJ possesses a better curative effect for hepatitis B with hepatic fibrosis.
Keywords:hepatic fibrosis   hepatitis, B, chronic   liverstagnation and spleen deficiency syndrome   Jianpi Ruangan Jian
本文献已被 CNKI 维普 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号